Middle East and Africa Biosimulation Market Report and Forecast 2024-2032

Middle East and Africa Biosimulation Market Report and Forecast 2024-2032

Middle East and Africa Biosimulation Market Report and Forecast 2024-2032

Middle East and Africa Biosimulation Market Size

The global biosimulation market was valued at USD 3.5 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the rising investments in the drug discovery activities. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.

Middle East and Africa Biosimulation Market Outlook

• The market size is influenced by the growing adoption of biosimulation techniques to identify potential drug candidates and expedite the development of safer and more targeted treatments with accurate dosing regimen.
• The market is witnessing multiple investment activities aimed at stimulating the growth of the pharmacometrics sector are expected to boost the Middle East and Africa biosimulation market share. Certara, Inc. invested in the Applied Pharmacometrics Training Fellowship program which started in January 2022 , to train African scientists in pharmacometrics and model-based analyses.
• It is estimated that more than 1 in 4 people are affected by non-communicable diseases in Saudi Arabia. This increasing prevalence of diseases is likely to create more emphasis on the adoption of biosimulation techniques, thereby fuelling the market demand.

Middle East and Africa Biosimulation Market Analysis

Biosimulation utilizes computational models and simulations to determine how drugs work, predict side effects and optimal dosing, and design better treatments for diseases. It leverages mathematical and computational techniques to analyze the dynamics of biological systems and how they will respond under different interventions. This approach is increasingly used to identify potential drug candidates due to its ability to accelerate drug development processes in a cost-effective way. The growing interest in in-silico drug discovery is expected to drive the Middle East and Africa biosimulation market growth.

The rising burden of non-communicable diseases also impacts the market dynamics in the region. Recent data states that cardiovascular diseases, cancer, diabetes , and chronic respiratory diseases (amongst four main non-communicable diseases) are responsible for the death of 22,000 people in Saudi Arabia every year. Further, it is estimated that more than 1 in 4 people are affected by any one of the 4 main non-communicable diseases, reflecting the urgent need for effective therapies. This increasing prevalence of diseases is anticipated to create more emphasis on the adoption of biosimulation techniques in order to expedite the development of safer and more targeted treatments. Consequently, this is poised to fuel the Middle East and Africa biosimulation market demand.

One of the major market trends is the increased investment in the pharmacometrics sector, which is likely to augment the demand for biosimulation software and services in the forecast period. For instance, in January 2022, Certara, Inc., a global leader in biosimulation, invested in the Applied Pharmacometrics Training Fellowship program to train African scientists in pharmacometrics and model-based analyses. This investment initiative by Certara in the fellowship program not only stimulates capacity building in Africa but also paves the way for potential market growth opportunities for the company in the region. Other factors such as the rising number of government-backed grants and research funding programs are also contributing to the market growth.

Middle East and Africa Biosimulation Market Segmentation  

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

Services

Software

Others

Market Breakup by Application

Drug Development

Drug Discovery

Other Applications

Market Breakup by Delivery Type

Subscription Model

Ownership Model

Others

Market Breakup by End User

Biotechnology and Pharmaceutical Companies

Research Institutes

Contract Research Organizations

Market Breakup by Country

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Leading Players in the Middle East and Africa Biosimulation Market

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Thermo Fisher Scientific INC.
• BIO-RAD Laboratories
• Illumina, INC.
• QIAGEN
• F. Hoffmann-La Roche LTD.
• Revvity
• Pacbio
• Agilent Technologies, INC.
• Sysmex Corporation
• BGI
• Eurofins Scientific SE

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

• What is the Middle East and Africa biosimulation market forecast outlook for 2024-2032?

The Middle East and Africa biosimulation market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 16.90% during the forecast period of 2024-2032 and is likely to reach a market value of USD 14.1 billion by 2032.

• What are the major factors aiding the Middle East and Africa biosimulation market demand?

The rising burden of chronic diseases and the growing interest in in-silico drug discovery is fuelling the demand for the market.

• What are the major Middle East and Africa biosimulation market trends?

One of the significant trends in the market involves rising investment in the pharmacometrics sector, which is likely to augment the demand for biosimulation software and services. For instance, Certara, Inc., invested in the Applied Pharmacometrics Training Fellowship program which started in January 2022, to train African scientists in pharmacometrics and model-based analyses.

• What is the market segmentation based on the product?

Based on the product, the market is segmented into software and services, among others.

• What is the market breakup by delivery model?

By delivery model, the market is divided into a subscription model and ownership model, among others.

• What are the major end users of the market?

End users of the market are pharmaceutical and biotechnology companies, contract research organizations, and academic and research institutes, among others.

• What are the applications of biosimulation?

Major applications of biosimulation include drug development and drug discovery, others

• What is the market segmentation by countries?

The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.

• Who are the key players involved in the Middle East and Africa biosimulation market?

The key players in the market are Thermo Fisher Scientific Inc., BIO-RAD Laboratories, ILLUMINA, INC., QIAGEN, F. Hoffmann-La Roche LTD., REVVITY, PACBIO, AGILENT TECHNOLOGIES, INC., SYSMEX CORPORATION, BGI, and EUROFINS SCIENTIFIC SE.

Meta description

The Middle East and Africa biosimulation market is poised for growth, driven by the expansion of the global market, which was valued at USD 3.5 billion in 2023 and is projected to grow at a CAGR of 16.90% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.